Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C60H72N8O6 |
Molar mass | 1001.286 g·mol−1 |
3D model (JSmol) | |
| |
|
Odalasvir (INN,[1] previously known as ACH-3102)[2][3] is an investigational new drug in development for the treatment of hepatitis C.[4] It is an NS5A inhibitor.[5] The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure.[6][7][8] It is under development by Achillion Pharmaceuticals.[citation needed]